Pharmafile Logo
Pharmafocus logo
Advanced Search

Eisai prepares ground for Halaven’s European launch

March 7, 2011
Sales and Marketing Cancer, EMBRACE, Eisai, Halaven, advanced breast cancer, breast cancer, eribulin

Eisai has published further details of a phase III trial of its first-in-class chemotherapy drug Halaven ahead of its hoped-for …

News

Eisai to cut 900 jobs ahead of Aricept patent loss

March 7, 2011
Sales and Marketing Aricept, Eisai, donepezil, generics, job cuts

Eisai is to cut around 900 jobs in Europe, the US and Japan over the next five years as it …

News
Novo Nordisk's Victoza

Novo’s Victoza beats Bydureon in head-to-head trial

March 4, 2011
Research and Development, Sales and Marketing Alkermes, Amylin, Byureon, Victoza, diabetes, exenatide, lilly, type II diabetes

Bydureon has been outperformed by rival Victoza in a head-to-trial, decimating shares in its co-developer Amylin and Alkermes, the company …

News

Onglyza expands European licence

March 4, 2011
Sales and Marketing AZ, AstraZeneca, BMS, Bristol-Myers Squibb, Onglyza, diabetes, renal impairment, saxagliptin, type II diabetes

European regulators have approved a licence extension for diabetes treatment Onglyza, making it the first drug in its class that …

News

First idiopathic pulmonary fibrosis drug approved

March 4, 2011
Sales and Marketing Esbriet, IPF, InterMune, Orphan Drugs, idiopathic pulmonary fibrosis, orphan drug

The first ever treatment for the potentially fatal lung disease idiopathic pulmonary fibrosis (IPF) has been approved in the EU. …

News
Sanofi's VTE avatar

Digital Pharma: online campaign directory updated

March 4, 2011
Medical Communications, Sales and Marketing Digital Pharma blog, Novartis, Pfizer, Sanofi-Aventis, VTE, diabetes, erectile dysfunction, pharmacist educaiton, venous thromboembolism, viagra

The latest update to the Digital Pharma links directory covers its online campaigns section and includes a pharmacist networking portal …

Feature

Market forces won’t produce needed restructure, warns King’s Fund

March 4, 2011
GP consortia, Health and Social Care Bill, Kings Fund, NHS, NHS Commissioning Board, NHS reforms, foundation trusts, hospital trusts, king's fund

Greater competition in the NHS is unlikely to bring about the restructuring needed in hospital services, according to The King’s …

News

Former McCann MD launches patient-focused agency

March 4, 2011
Medical Communications Craig Mills, Frontera, healthcare communications agency, medical communications

An agency specialising in professional, consumer and public health has been launched by a former managing director at McCann Healthcare. …

News
ABPI Code of Practice

Medical bodies back ABPI Code changes

March 4, 2011
Medical Communications ABPI, ABPI Code of Practice, Code of Practice, GMC, INFORCE, Nottingham, Royal College of Physicians, industry relations, trust

Leading medical organisations have signed a joint declaration backing the forthcoming changes to UK pharma’s self-regulatory Code of Practice. In …

News

NICE rejects Lucentis for diabetic oedema

March 4, 2011
Sales and Marketing Lucentis, NICE, Novartis, VEGF, Vascular Endothelial Growth Factor, diabetic oedema, raibizumab

NICE’s draft guidance has not recommended Lucentis for diabetic oedema after ‘faulty analysis’ from manufacturer Novartis was found not to …

News
Blog footer

Digital Pharma: European doctors’ communities collaborate

March 3, 2011
Medical Communications, Sales and Marketing Coliquio, Digital Pharma blog, Doctors.net.uk, online doctors communities

Two of Europe’s leading medical professional communities have signed a strategic alliance that will see them collaborate on multi-market digital …

News
quintiles_jim_mcdermott

Jim McDermott to lead Quintiles Market Intelligence

March 3, 2011
Sales and Marketing Jim McDermott, Quintiles, appointment, sales and marketing

Quintiles has appointed Jim McDermott as managing director of the Market Intelligence practice within its Consulting group. The practice provides …

Appointment
Science minister David Willetts

Universities to ‘pick up pharma’s R&D mantle’ after Pfizer closure

March 3, 2011
Research and Development Kent, Pfizer, Sandwich, Science and Technology Select Committee, UK research, UK science, job cuts

Science in the UK will have to focus on contractually-based research in the future as pharma’s R&D presence in the …

News
GlaxoSmithKline's London headquarters

GSK to reimburse tuition fees for UK trainees

March 3, 2011
Business Services, Research and Development, Sales and Marketing GSK, GlaxoSmithKline, UK science, careers, graduate, graduate recruitment

GlaxoSmithKline is set to reimburse UK university tuition fees paid by its trainees from 2012. Each year, GSK recruits between …

News

Forest’s COPD drug approved in US

March 3, 2011
Sales and Marketing COPD, Daliresp, Daxas, Forest, Forest Laboratories, chronic obstructive pulmonary disease, roflumilast

Daliresp (roflumilast) has been approved by the FDA to treat severe chronic obstructive pulmonary disease. Forest Laboratories’ once-daily pill is …

News
The RNA interference process

RNA interference – still the great white hope?

March 3, 2011
Manufacturing and Production, Research and Development RNA interference, rnai

The emerging field of RNA interference – also known as ‘gene silencing’ – is one of the most promising in …

Feature

NHS competition plans provide focus for dissent

March 3, 2011
Health and Social Care Bill, NHS, NHS reforms

Confusion and controversy surround the government plans to introduce greater levels of competition into the NHS, with many stakeholder groups …

Feature
EMD Serono headquarters

FDA knocks back Merck KGaA’s oral MS drug

March 2, 2011
Sales and Marketing Cladribine, EMD Serono, FDA, MS, Merck KGaA, Movectro, multiple sclerosis, oral MS drugs

US authorities have turned down Merck KGaA’s new drug application for its oral relapsing-remitting multiple sclerosis treatment Movectro. The FDA …

News

UCB teams up with Harvard for CNS research

March 2, 2011
Research and Development CNS, Harvard, UCB, academia, academic research, immunology

UCB has signed a new research collaboration with Harvard University that will focus on central nervous system and immunology therapies. …

News
brecon_kay_ohagan

Boehringer’s Kay O’Hagan moves to Brecon

March 2, 2011
Manufacturing and Production, Research and Development Brecon, Kay O'Hagan, appointment, manufacturing and production, research and development

Kay O’Hagan has joined commercial packaging and clinical trials supply services company Brecon Pharmaceuticals as director of quality assurance and …

Appointment
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026